Pulmonary involvement in microscopic polyangiitis

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 5, 2005, Pages 447-451

  Collins, Christopher E ^a   Quismorio Jr , Francisco P ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alveolar hemorrhage; Microscopic polyangiitis; Pulmonary manifestations; Vasculitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB;

BLADDER CANCER; BRONCHOSCOPY; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; ENVIRONMENTAL FACTOR; FELTY SYNDROME; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; HEMOPTYSIS; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; INFERTILITY; INTENSIVE CARE UNIT; LABORATORY TEST; LUNG BIOPSY; LUNG HEMORRHAGE; LUNG INJURY; LUNG VENTILATION; LUNG VENTILATION PERFUSION RATIO; MICROSCOPIC POLYANGIITIS; PLASMAPHERESIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 24744472044     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000170520.63874.fb     Document Type: Review

References (53)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192.
2. Jennette JC, Thomas DB, Falk RJ. Microscopic polyangiitis (microscopic polyarteritis). Semin Diagn Pathol 2001; 18:3-13.
3. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003; 49:388-393.
4. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51:92-99.
5. Agard C, Mouthon L, Mahr A, Guillevin L. Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? Arthritis Rheum 2003; 49:709-715.
6. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98:97-111. This paper reviews the various clinical features and mortality of patients with MPA.
7. Tsuchiya N, Kobayashi S, Kawasaki A, et al. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. J Rheumatol 2003; 30:1534-1540.
8. Bartfai Z, Gaede KI, Russell KA, et al. Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. Clin Immunol 2003; 109:330-337.
9. Izzedine H, Rosenheim M, Launay-Vacher V, et al. Epidemiology of microscopic polyarteritis: a 16-year study. Kidney Int 2004; 65:741.
10. Lane SE, Watts RA, Bentham G, et al. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003; 48:814-823.
11. Pelclova D, Bartunkova J, Fenclova Z, et al. Asbestos exposure and antineutrophil cytoplasmic antibody (ANCA) positivity. Arch Environ Health 2003; 58:662-668.
12. Philteos GS, Coverett K, Chibbar R, et al. Asbestosis and probable microscopic polyangiitis. Can Respir J 2004; 11:359-362.
13. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-4119.
14. Rutgers A, Heeringa P, Tervaert JW. The role of myeloperoxidase in the pathogenesis of systemic vasculitis. Clin Exp Rheumatol 2003; 21:S55-S63.
15. Ando Y, Okada F, Matsumoto S, Mori H. Thoracic manifestation of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease: CT findings in 51 patients. J Comput Assist Tomogr 2004; 28:710-716. This excellent review of thoracic CT scans in patients with MPO-ANCA associated vasculitis also examines the correlations between pathology, imaging, and clinical disease activity.
16. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93:398-401. This paper describes a fascinating case of apparent maternal-fetal transfer of MPO-ANCA, resulting in neonatal MPA.
17. Lauque D, Cadranel J, Lazor R, et al. Microscopic polyangiitis with alveolar hemorrhage: a study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies Orphelines' Pulmonaires (GERM'O'P). Medicine (Baltimore) 2000; 79:222-233.
18. Griffith M, Brett S. The pulmonary physician in critical care: illustrative case 3: pulmonary vasculitis. Thorax 2003; 58:543-546.
19. Goto H, Ogura T, Takahasi H, et al. [A case of MPO-ANCA-related vasculitis with chronic alveolar hemorrhage]. Nihon Kokyuki Gakkai Zasshi 2004; 42:266-271.
20. Brugiere O, Raffy O, Sleiman C, et al. Progressive obstructive lung disease associated with microscopic polyangiitis. Am J Respir Crit Care Med 1997; 155:739-742.
21. Nada AK, Torres VE, Ryu JH, et al. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990; 65:847-856.
22. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 2004; 9:190-196.
23. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003; 123:297-301.
24. Takeda Y, Aoki A, Tsuji T, et al. [A case of non-specific interstitial pneumonia in patient with microscopic polyangiitis]. Ryumachi 2003; 43:654-659.
25. Ortiz-Santamaria V, Olive A, Holgado S, Muchart J. Pulmonary aneurysms in microscopic polyangiitis. Clin Rheumatol 2003; 22:498-499.
26. Park J, Banno S, Sugiura Y, et al. Microscopic polyangiitis associated with diffuse panbronchiolitis. Intern Med 2004; 43:331-335.
27. Watz H, Hammerl P, Matter C, et al. [Bronchioloalveolar carcinoma of the lung associated with a highly positive pANCA-titer and clinical signs of microscopic polyangiitis]. Pneumologie 2004; 58:493-498.
28. Neumann I, Mirzaei S, Birck R, et al. Expression of somatostatin receptors in inflammatory lesions and diagnostic value of somatostatin receptor scintigraphy in patients with ANCA-associated small vessel vasculitis. Rheumatology (Oxford) 2004; 43:195-201.
29. Savige J, Dimech W, Fritzler M, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies: quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120:312-318.
30. Wiik A. Autoantibodies in vasculitis. Arthritis Res Ther 2003; 5:147-152.
31. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multi-organ dysfunction. Arthritis Rheum 2003; 49:151-155.
32. Merkel PA, Polisson RP, Chang Y, et al. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126:866-873.
33. Flores-Suarez LF, Cabiedes J, Villa AR, et al. Prevalence of antineutrophil cytoplasmic autoantibodies in patients with tuberculosis. Rheumatology (Oxford) 2003; 42:223-229.
34. Teixeira L, Mahr A, Jaureguy F, et al. Low seroprevalence and poor specificity of antineutrophil cytoplasmic antibodies in tuberculosis. Rheumatology (Oxford) 2005; 44:247-250.
35. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum 2003; 49:93-100.
36. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36-44.
37. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278-283.
38. Assaf C, Mewis G, Orfanos CE, Geilen CC. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol 2004; 150:598-600.
39. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463-469.
40. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15:717-721. This paper describes an open-label prospective trial of infliximab as adjuvant therapy for acute and refractory ANCA-associated vasculitis.
41. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361. These results from the Wegener's Granulomatosis Etanercept Trial demonstrate that etanercept is not effective for the maintenance of remission in WG.
42. Kallenbach M, Duan H, Ring T. Rituximab induced remission in a patient with Wegener's granulomatosis. Nephron Clin Pract 2005; 99:c92-c96.
43. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-268. These authors describe various clinical and serologic responses in 11 patients with ANCA-associated vasculitis who received rituximab, and discuss possible pathologic mechanisms.
44. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33-39.
45. Akioka Y, Hattori M, Kawaguchi H, Ito K. A case of chronic relapsing ANCA-associated microscopic polyangiitis successfully treated with plasma exchange. Ther Apher Dial 2004; 8:223-226.
46. Klemmer PJ, Chalermskulrat W, Reif MS, et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-1153.
47. Henke D, Falk RJ, Gabriel DA. Successful treatment of diffuse alveolar hemorrhage with activated factor VII. Ann Intern Med 2004; 140:493-494.
48. Matsumoto T, Ueki K, Tamura S, et al. Extracorporeal membrane oxygenation for the management of respiratory failure due to ANCA-associated vasculitis. Scand J Rheumatol 2000; 29:195-197.
49. Agarwal HS, Taylor MB, Grzeszczak MJ, et al. Extra corporeal membrane oxygenation and plasmapheresis for pulmonary hemorrhage in microscopic polyangiitis. Pediatr Nephrol 2005; 20:526-528.
50. Hayes-Bradley C. Hypoxia from vasculitic pulmonary haemorrhage improved by prone position ventilation. Br J Anaesth 2004; 92:754-757. This author describes the successful use of prone position ventilation in the management of pulmonary hemorrhage secondary to vasculitis.
51. Merkel PA, Choi HK, Niles JL. Evaluation and treatment of vasculitis in the critically ill patient. Crit Care Clin 2002; 18:321-344.
52. Weidner S, Geuss S, Hafezi-Rachti S, et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19:1403-1411.
53. Hogan SL, Nachman PH, Wilkman AS, et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:23-32.